DKCM
APGE

Davidson Kempner Capital Management’s Apogee Therapeutics APGE Stock Holding History

Davidson Kempner Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,000
Closed -$213K – 250
2023
Q3 		$213K Buy
+10,000
New +$220K ﹤0.01% 164

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Davidson Kempner Capital Management's APGE Position: Q4 2023 in Review

Davidson Kempner Capital Management sold out of Apogee Therapeutics (APGE) in Q4 2023, closing a stake of 10,000 shares — an estimated $213K sold.

Davidson Kempner Capital Management first reported a position in APGE in Q3 2023 and held it in 1 quarter. The position peaked at $213K in Q3 2023. 85 funds tracked by Wall St. Rank hold APGE as of Q4 2023.

  • Davidson Kempner Capital Management reported no remaining Apogee Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 10,000 Apogee Therapeutics shares in Q4 2023, an estimated $213K.
  • Davidson Kempner Capital Management first reported a position in Apogee Therapeutics in Q3 2023 and held it in 1 quarter.
  • Davidson Kempner Capital Management's Apogee Therapeutics position peaked at $213K in Q3 2023.
  • 85 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2023.

Based on Davidson Kempner Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.